Document Type

Article

Publication Date

1-12-2024

Comments

This article is the author's final published version in Journal of Biomedical Science, Volume 31, Issue 1, January 2024, Article number 6.

The published version is available at https://doi.org/10.1186/s12929-024-00996-w.

Copyright © The Author(s) 2024

Abstract

The developments of antibodies for cancer therapeutics have made remarkable success in recent years. There are multiple factors contributing to the success of the biological molecule including origin of the antibody, isotype, affinity, avidity and mechanism of action. With better understanding of mechanism of cancer progression and immune manipulation, recombinant formats of antibodies are used to develop therapeutic modalities for manipulating the immune cells of patients by targeting specific molecules to control the disease. These molecules have been successful in minimizing the side effects instead caused by small molecules or systemic chemotherapy but because of the developing therapeutic resistance against these antibodies, combination therapy is thought to be the best bet for patient care. Here, in this review, we have discussed different aspects of antibodies in cancer therapy affecting their efficacy and mechanism of resistance with some relevant examples of the most studied molecules approved by the US FDA.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

38216921

Language

English

Download

Included in

Oncology Commons

Share

COinS